- Chief Medical Officer Dr. Sam Barone to join the Emerging Innovations in Retinal Therapies panel; Company to present an update on MOGENRY®in the Retina Drug Delivery New Targets Showcase at Eyecelerator 2026.
- Four-year REMAIN data from the RESTORE Phase 2b/3 trial of MCO-010 in retinitis pigmentosa and a scientific poster on dry AMD to be presented at the AAO 2026 Annual Meeting, October 8–13, 2026, in New Orleans, Louisiana.
ダラス, Oct. 6, 2026 /PRNewswire/ — ナノスコープ・セラピューティクス, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that its optogenetics gene therapy (MOGENRY, MCO-010) will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) 2026 annual meeting taking place October 8–13, 2026, in New Orleans. Additionally, the company will participate in Eyecelerator@AAO 2026 with a company presentation and panel participation. Eyecelerator brings together ophthalmic innovators, industry leaders, clinicians, and investors to accelerate the development of new therapies and technologies in eye care. The AAO Annual Meeting is the world’s largest gathering of ophthalmologists and eye care professionals.
Eyecelerator Presentation Details:
Eyecelerator 2026, Ernest N. Morial Convention Center
パネル： Emerging Innovations in Retinal Therapies
パネリスト： Sam Barone, MD, Chief Medical Officer
日時： Thursday, October 8, 2026, 10:45–11:30 AM CT
位置： La Nouvelle Ballroom C
Company Presentation: Retina Drug Delivery & New Targets Showcase
プレゼンター： Paul Hallen, Chief Operating Officer
日時： Thursday, October 8, 2026, 1:00–1:05 PM CT
位置： Rooms 252–254
AAO Presentation Details:
AAO 2026 Annual Meeting, Ernest N. Morial Convention Center
プレゼンテーション: Lasting vision Improvement in Retinitis Pigmentosa: REMAIN 4-Year Study Data From the RESTORE Phase 2b/3 Trial of MCO-010 Optogenetic Therapy
セッション： PA044
プレゼンター： Kenneth C. Fan, MD
日時： Sunday, October 11, 2026, 11:42–11:49 AM CT
位置： Rooms 255–257
Scientific Poster: Vision Improvement in Dry AMD With Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 RCT
セッション： PO624
プレゼンター： David S. Boyer, MD
Availability: On demand
During the panel, Dr. Barone will join fellow industry leaders to discuss emerging approaches in retinal therapeutics, including the potential of mutation-agnostic optogenetic gene therapy for patients with advanced retinal degeneration. In the Showcase presentation, Mr. Hallen will provide an update on Nanoscope’s progress toward potential global approval of its lead asset, MOGENRY® (ソンピレチゲネ・イステパルボベク; MCO-010), for the treatment of inherited retinal dystrophies, including the status of the Company’s Biologics License Application (BLA), そして Japan New Drug Application (JNDA), currently under FDA and PMDA review respectively. At AAO 2026, Dr. Fan will present four-year data from the REMAIN study of patients treated in the RESTORE Phase 2b/3 trial, highlighting the durability of vision improvement with MCO-010 in retinitis pigmentosa. Dr. David S. Boyer will also present a scientific poster, available on demand, on vision improvement with sonpiretigene isteparvovec in dry AMD from the first direct-to-Phase 2 randomized controlled trial. Members of the Nanoscope leadership team will be available to meet with retina specialists, investors, and potential partners throughout Eyecelerator and AAO 2026.
Nanoscope team members will be available at Booth 2564 for the duration of the AAO conference.
About MOGENRY (sonpiretigene isteparvovec; MCO-010)
Nanoscope’s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope’s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope’s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows. MOGENRY is under review by the FDA for the treatment of RP with severe vision loss and under priority review by the PMDA and MHLW for the treatment of IRDs in Japan. The 2026 Nobel Prize in Physiology or Medicine was recently awarded to the three scientists who pioneered optogenetics, the scientific foundation that Nanoscope’s development programs, including MOGENRY, are built upon.
ナノスコープ・セラピューティクスについて
ナノスコープ・セラピューティクスは、網膜変性疾患により失明した数百万人の患者のために、疾患の種類を問わず視力を回復させる光遺伝学的治療法を開発しています。網膜色素変性症（RP）を対象とした多施設共同無作為化二重盲検プラセボ対照臨床試験であるRESTORE第2b/3相試験で良好な結果が得られたことを受け、NCT04945772), the FDA has accepted and filed the Company’s BLA for MOGENRY, and the PMDA has accepted for priority review the Company’s NDA for MOGENRY for the treatment of IRDs in Japan. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126）であり、2026年に第3相登録試験を開始する予定です。MCO-010は、RPとSDの両方でFDAのファストトラックおよびオーファンドラッグ指定を受けており、SDについてはRMAT指定も受けています。また、非症候性および症候性の桿体および錐体優位性ジストロフィー、ならびに黄斑ジストロフィーを対象としたEMAのオーファン指定も受けています。MCO-010は、日本では遺伝性網膜ジストロフィー（IRD）の先駆け指定およびオーファン指定を受けており、サウジアラビアではIRDのオーファン指定を受けています。地理的萎縮症に対するMCOの第2相プログラムは2026年に開始される予定であり、IND準備中の他のプログラムにはレーバー先天性黒内障（LCA）が含まれます。.
Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn.
接触：
ナノスコープ・セラピューティクス社
(817) 857-1186
PR@nanostherapeutics.com
出典 ナノスコープ・セラピューティクス